OMERS ADMINISTRATION Corp Has $2.72 Million Holdings in ResMed Inc. (NYSE:RMD)

OMERS ADMINISTRATION Corp decreased its position in ResMed Inc. (NYSE:RMD - Free Report) by 17.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,871 shares of the medical equipment provider's stock after selling 2,518 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in ResMed were worth $2,715,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of RMD. Invesco Ltd. grew its position in ResMed by 32.2% in the fourth quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider's stock worth $531,706,000 after buying an additional 566,046 shares during the last quarter. Norges Bank bought a new stake in shares of ResMed during the 4th quarter worth $118,605,000. Captrust Financial Advisors grew its holdings in shares of ResMed by 813.4% in the 4th quarter. Captrust Financial Advisors now owns 443,340 shares of the medical equipment provider's stock worth $101,387,000 after acquiring an additional 394,803 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of ResMed by 133.6% in the 4th quarter. AQR Capital Management LLC now owns 625,054 shares of the medical equipment provider's stock worth $142,944,000 after acquiring an additional 357,466 shares during the last quarter. Finally, BLI Banque de Luxembourg Investments acquired a new stake in shares of ResMed during the fourth quarter worth $74,793,000. Institutional investors own 54.98% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on RMD. JPMorgan Chase & Co. increased their price target on ResMed from $286.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday, April 24th. Mizuho set a $265.00 target price on shares of ResMed in a report on Wednesday, April 16th. Royal Bank of Canada boosted their price target on shares of ResMed from $247.00 to $255.00 and gave the company a "sector perform" rating in a report on Thursday, April 24th. Stifel Nicolaus reduced their price target on shares of ResMed from $250.00 to $240.00 and set a "hold" rating for the company in a research report on Wednesday, March 5th. Finally, Piper Sandler lowered their price objective on shares of ResMed from $260.00 to $248.00 and set a "neutral" rating on the stock in a research report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $258.83.

Insider Activity at ResMed

In related news, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $227.71, for a total value of $455,420.00. Following the completion of the sale, the director now directly owns 75,218 shares in the company, valued at approximately $17,127,890.78. This represents a 2.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Michael J. Farrell sold 8,009 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $229.20, for a total transaction of $1,835,662.80. Following the transaction, the chief executive officer now directly owns 455,472 shares in the company, valued at $104,394,182.40. The trade was a 1.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,949 shares of company stock valued at $11,335,320. 0.71% of the stock is currently owned by corporate insiders.

ResMed Stock Up 1.3%

Shares of NYSE RMD traded up $3.17 during mid-day trading on Friday, reaching $251.75. The company had a trading volume of 839,605 shares, compared to its average volume of 1,019,252. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. ResMed Inc. has a twelve month low of $179.42 and a twelve month high of $263.05. The stock's 50 day moving average is $225.34 and its 200-day moving average is $234.17. The stock has a market capitalization of $36.91 billion, a PE ratio of 29.72, a price-to-earnings-growth ratio of 1.53 and a beta of 0.78.

ResMed (NYSE:RMD - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 EPS for the quarter, beating analysts' consensus estimates of $2.36 by $0.01. ResMed had a return on equity of 26.17% and a net margin of 25.34%. The firm had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter in the previous year, the company posted $2.13 earnings per share. The business's quarterly revenue was up 7.9% compared to the same quarter last year. As a group, equities analysts anticipate that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Thursday, May 8th will be issued a $0.53 dividend. The ex-dividend date is Thursday, May 8th. This represents a $2.12 dividend on an annualized basis and a yield of 0.84%. ResMed's dividend payout ratio is currently 23.79%.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.